Wuxi Apptec (603259.SH) recently released its Q3 2025 financial report, showing a significant rebound in performance. However, the dramatic fluctuations in "non-recurring gains and losses" raise questions about whether the company is employing financial engineering.

**Earnings Growth Forms a "Deep U" Curve** Wuxi Apptec’s net profit attributable to shareholders surged 84.84% YoY in the first three quarters of 2025, marking a sharp recovery from the declines in 2023 (-1.63%) and 2024 (9%). However, this rebound was heavily influenced by non-recurring gains, which totaled ¥2.55 billion in Q1-Q3 2025—the highest in over a decade. In contrast, 2024 saw a record non-recurring loss of ¥538 million.

Excluding these one-time items, Wuxi Apptec’s adjusted net profit grew 42.51% YoY, still robust but notably lower than the headline figure. Analysts caution that reliance on non-recurring gains—such as the ¥3.22 billion profit from selling shares in Cayman Inc.—lacks sustainability.

**Asset Sales and Valuation Concerns** Concurrently, Wuxi Apptec announced plans to sell two wholly-owned subsidiaries for ¥2.8 billion to Hillhouse Capital, a long-time investor. The subsidiaries, specializing in clinical research services (CRO), reported combined net assets of ¥969 million—far below the sale price. While the deal could boost short-term profits, their price-to-sales (PS) and price-to-earnings (PE) ratios (2.4x and 32.2x, respectively) lag behind peers like Tigermed (300347.SZ) and Novotech (301333.SZ).

**Leadership and Market Challenges** Founder Li Ge, dubbed the "IPO Genius" for orchestrating Wuxi Apptec’s multi-market listings, faces headwinds. The U.S. Biosecurity Act, which once hammered its stock, remains a latent risk given its heavy reliance on American clients. Still, strong demand in chemical services (up 29.28% YoY) and a ¥59.88 billion order backlog suggest resilience.

However, Li’s recent plan to sell up to 2% of his stake (potentially ¥5.8 billion) triggered an 8.47% stock drop, reigniting investor skepticism.

**Conclusion** While Wuxi Apptec’s 2025 recovery appears impressive, its reliance on one-time gains and high-profile divestments invites scrutiny. Whether Li Ge can steer the company through cyclical and geopolitical challenges remains to be seen.

As of November 3, Wuxi Apptec’s shares closed at ¥96.41 (-3.01%), with a market cap of ¥287.7 billion.